Skip to content
The Policy VaultThe Policy Vault

Humira and biosimilarsCareFirst (Caremark)

uveitis (non-infectious intermediate, posterior, and panuveitis)

Initial criteria

  • Age ≥ 2 years
  • Member previously received biologic indicated for non-infectious uveitis OR inadequate response to corticosteroids or immunosuppressive therapy (azathioprine, cyclosporine, methotrexate, mycophenolate mofetil) OR intolerance/contraindication to such therapies

Approval duration

12 months